Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

TRULICITY® (dulaglutide): QTC Interval

At supratherapeutic doses (4 and 7 mg), dulaglutide does not prolong QTc.

Detailed Information

The effect of dulaglutide on cardiac repolarization was thoroughly tested in a QTc study and found that at supratherapeutic doses, dulaglutide 4 mg and dulaglutide 7 mg did not prolong QTc.1

Enclosed Prescribing Information

TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly


1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


QTc = corrected QT interval 

Date of Last Review: January 03, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical